Skip to content
  • Clinical Studies
  • Pharma SOP’s
  • Pharma tips
  • Pharma Books
  • Stability Studies
  • Schedule M

Pharma GMP

Your Gateway to GMP Compliance and Pharmaceutical Excellence

  • Home
  • Quick Guide
  • Toggle search form

Cross-Verify Certificate of Analysis (COA) With Raw Data for GMP Assurance

Posted on May 21, 2025 By digi

Cross-Verify Certificate of Analysis (COA) With Raw Data for GMP Assurance

Always Cross-Verify COA Results With Original Raw Data

Remember: Relying solely on a Certificate of Analysis (COA) without raw data verification is not GMP compliant—cross-verification is essential.

Why This Matters in GMP

The Certificate of Analysis (COA) summarizes key quality attributes of materials or finished products. However, without verification against raw data—chromatograms, calculations, weights, and observations—its authenticity and accuracy remain unchecked. Accepting a COA at face value may expose the facility to falsified data, supplier negligence, or analytical errors. GMP requires traceability and validation of data used for quality decisions. Verifying raw data ensures that reported values are accurate, derived from validated methods, and meet specifications. It also supports root cause analysis in case of complaints or deviations.

Also Read:  Never Use Trial Batches for Commercial Release Under GMP

Regulatory and Compliance Implications

FDA 21 CFR Part 211.194 mandates that laboratory test results be backed by raw data. WHO GMP and Schedule M emphasize the review of source data before batch disposition. EU GMP Annex 15 requires verification of third-party COAs during supplier qualification and material release. Regulatory auditors expect complete traceability from reported values to raw records. Failing to cross-verify COAs may lead to data integrity observations, especially when using outsourced testing or third-party vendors. QA must review original test data for all critical parameters before accepting results.

Implementation Best Practices

  • Establish SOPs requiring QA review of all analytical raw data corresponding to COA entries.
  • Maintain data review checklists for identity, assay, impurities, and microbial results.
  • Request raw data from vendors during material evaluation and audit third-party labs periodically.
  • Train staff to verify chromatograms, calculation sheets, and equipment logs alongside COAs.
  • Ensure that each COA file includes a reference to raw data location and reviewer initials.
Also Read:  Ensuring GMP Compliance with FDA Standards in Pharma Supply Chains

Regulatory References

  • FDA 21 CFR Part 211.194 – Laboratory Records
  • EU GMP Annex 15 – Qualification and Validation
  • WHO GMP – Quality Control Documentation
  • Schedule M – Certificate of Analysis Verification
GMP Tips Tags:analytical review, audit readiness, certificate of analysis, COA verification, data integrity, documentation practices, falsification prevention, FDA 21 CFR Part 211, GMP compliance, laboratory records, material release, QA oversight, raw data review, Schedule M, WHO GMP

Post navigation

Previous Post: Understanding Inspection Frequency and Risk Scoring Models Used Globally
Next Post: GMP Surveillance Audits: Global Best Practices

Menu

  • GMP Basics
    • Introduction to GMP
    • What is cGMP?
    • Key Principles of GMP
    • Benefits of GMP in Pharmaceuticals
    • GMP vs. GxP (Good Practices)
  • Regulatory Agencies & Guidelines
    • WHO GMP Guidelines
    • FDA GMP Guidelines
    • MHRA GMP Guidelines
    • SCHEDULE – M – Revised
    • TGA GMP Guidelines
    • Health Canada GMP Regulations
    • NMPA GMP Guidelines
    • PMDA GMP Guidelines
    • EMA GMP Guidelines
  • GMP Compliance & Audits
    • How to Achieve GMP Certification
    • GMP Auditing Process
    • Preparing for GMP Inspections
    • Common GMP Violations
    • Role of Quality Assurance
  • Quality Management Systems (QMS)
    • Building a Pharmaceutical QMS
    • Implementing QMS in Pharma Manufacturing
    • CAPA (Corrective and Preventive Actions) for GMP
    • QMS Software for Pharma
    • Importance of Documentation in QMS
    • Integrating GMP with QMS
  • Pharmaceutical Manufacturing
    • GMP in Drug Manufacturing
    • GMP for Biopharmaceuticals
    • GMP for Sterile Products
    • GMP for Packaging and Labeling
    • Equipment and Facility Requirements under GMP
    • Validation and Qualification Processes in GMP
  • GMP Best Practices
    • Total Quality Management (TQM) in GMP
    • Continuous Improvement in GMP
    • Preventing Cross-Contamination in Pharma
    • GMP in Supply Chain Management
    • Lean Manufacturing and GMP
    • Risk Management in GMP
  • Regulatory Compliance in Different Regions
    • GMP in North America (FDA, Health Canada)
    • GMP in Europe (EMA, MHRA)
    • GMP in Asia (PMDA, NMPA, KFDA)
    • GMP in Emerging Markets (GCC, Latin America, Africa)
    • GMP in India
  • GMP for Small & Medium Pharma Companies
    • Implementing GMP in Small Pharma Businesses
    • Challenges in GMP Compliance for SMEs
    • Cost-effective GMP Compliance Solutions for Small Pharma Companies
  • GMP in Clinical Trials
    • GMP Compliance for Clinical Trials
    • Role of GMP in Drug Development
    • GMP for Investigational Medicinal Products (IMPs)
  • International GMP Inspection Standards and Harmonization
    • Global GMP Inspection Frameworks
    • WHO Prequalification and Inspection Systems
    • US FDA GMP Inspection Programs
    • EMA and EU GMP Inspection Practices
    • PIC/S Role in Harmonized Inspections
    • Country-Specific Inspection Standards (e.g., UK MHRA, US FDA, TGA)
  • GMP Blog
Widget Image
  • Do Not Leave Batch Records in Uncontrolled Office Areas

    Do Not Leave Batch Records… Read more

GMP Tips

  • Do Not Leave Batch Records in Uncontrolled Office Areas
  • Implement UV Sterilization Protocols in GMP Change Rooms
  • Do Not Allow Incomplete Documentation During GMP Batch Record Review
  • Assign Identification Numbers to All Cleaning Tools for Traceability
  • Never Use Damaged Sieves or Mesh During Granulation in GMP
  • Conduct Alarm Challenge Tests to Validate Critical GMP System Responses
  • Do Not Ignore Elevated Noise Levels in GMP Classified Areas
  • Cross-Verify Certificate of Analysis (COA) With Raw Data for GMP Assurance
  • Do Not Store Chemicals Without Material Safety Data Sheets (MSDS)
  • Perform Visual Inspection of Vials Using Qualified Lighting Conditions

More about GMP Tips :

  • Do Not Allow Incomplete Documentation During GMP Batch Record Review
  • Conduct Risk Assessments Before Implementing Process Changes
  • Monitor Utility Systems Like Water and Compressed Air for GMP Quality
  • Never Use Photocopies as Originals for GMP Quality Documents
  • Conduct Periodic Pest Control Audits in GMP Storage Areas
  • Use Material Transfer Notes (MTNs) When Moving Raw Materials
  • Avoid Manual Data Corrections Without Proper Justification
  • Update GMP Training Records After Every Training Session
  • Implement Controlled Access to Data Entry Terminals in GMP Areas
  • Never Use Trial Batches for Commercial Release Under GMP
  • Never Approve Batches Without Complete Analytical Test Reports
  • Do Not Wear Jewelry or Cosmetics Inside Cleanroom Areas
  • Verify Reagent Expiry Dates Before Use in QC Laboratories
  • Review Equipment Logbooks for Completeness During GMP Audits
  • Do Not Record Test Results Before Completing the Analysis

Copyright © 2025 Pharma GMP.

Powered by PressBook WordPress theme